Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risdiplam - A Phase I, Open-Label, Multi-Period Crossover Study to Investigate the Safety, Food Effect, Bioavailability and Bioequivalence of Oral Doses of Two Different Formulations in Healthy Subjects

NCT04718181 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04718181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04718181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risdiplam - A Phase I, Open-Label, Multi-Period Crossover Study to Investigate the Safety, Food Effect, Bioavailability and Bioequivalence of Oral Doses of Two Different Formulations in Healthy Subjects
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
February 1, 2021
Completion date
January 28, 2023
Enrollment
131 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

muscular atrophy, spinal